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Abstract
Background: ’Intrinsic’ resistance to retroviral infection was first recognised with the Friend virus susceptibility
gene (Fv1), which determines susceptibility to murine leukaemia virus (MLV) infection in different murine species.
Similarly, the tripartite motif (TRIM) family of proteins determine lentiviral restriction in a primate host-species
specific manner. For example rhesus TRIM5a (rhTRIM5a) can potently restrict HIV-1 infection while human TRIM5a
(huTRIM5a) only has a mild effect on SIVmac and HIV-1 infectivity (Lv1). Human TRIM5a is able to restrict MLV-N
virus replication, but is ineffective against MLV-B or MLV-NB virus infection. Lv2 restriction of some HIV-2 viruses is
seen in human cells. Like Lv1, Lv2 is a post-entry restriction factor, whose viral determinants have been mapped to
the viral capsid (CA). Unlike Lv1, however, Lv2 is determined by envelope (Env) in addition to CA. Here we present
evidence of a novel Env determined post entry restriction to infection in human cells of pseudotyped MLV-B and
MLV-NB cores.
Results: We generated retroviral vectors pseudotyped with various gamma and lentiviral Envs on MLV-B and -NB
CAs containing a green fluorescent protein (GFP) reporter. Flow cytometry was used to determine transduction
efficiencies in NP2/CD4/CXCR4 (glioma cell line stably transduced with the HIV receptors) and HeLa/CD4 cell lines.
The HeLa/CD4 cell line restricted both MLV CAs in an Env dependent manner, compared to NP2/CD4/CXCR4 cells.
Quantitative polymerase chain reaction (QT-PCR) analysis of reverse transcription (RT) transcripts demonstrates that
this restriction occurs at a post entry and RT level. siRNA knockdown of huTRIM5a ruled out a direct role for this
cellular component in mediating this restriction. We describe a previously unobserved Env determined restriction
of MLV-B and MLV-NB CAs in HeLa/CD4 cells when pseudotyped with HIV-2 and RD114 Envs, but not gibbon ape
leukaemia virus (GALV), HIV-1 or Amphotrophic (Ampho) Envs.
Conclusions: Our data further demonstrate the variability of Env and CA mediated susceptibility to post entry host
cell restriction. We discuss the relevance of these findings in light of the growing evidence supporting the
complexities involved in innate host immunity to retroviral infection.
Background
Retroviruses can cause a variety of diseases in their host
species. Over-expression, integration near oncogenic
loci, or the hosts’ response to the proteins encoded by
retroviral genes determine the type of disease manifested
[1]. Greater understanding of host immunity against
retroviruses is pertinent in the era of a global HIV/AIDS
epidemic.
The murine leukaemia viruses (MLVs) are members of
the gamma-retrovirus genus of the Retroviridae family.
The diseases caused by MLVs include lymphomas and
leukaemias. Studies on Friend MLV led to the discovery
of the archetypal regulation or restriction of viral infec-
tion by intrinsic host-cell defence mechanisms. Friend
virus susceptibility factor (Fv1) is a dominant allele
expressed in mice or cell lines adapted from specific
species of mice that confers resistance to different MLV
strains [2]. Hence, MLV-N strains (N-tropic MLVs) are
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b/b genotype, and
MLV-B strains are unable to infect mice with the Fv
n/n
genotype. Mice with the Fv
n/b genotype are resistant to
both strains of MLVs but are susceptible to viruses that
are both N and B tropic, such as Moloney MLV (MLV-
NB) [3]. Fv1 is a saturable gag-like element expressed
from a murine endogenous retrovirus-L (MuERV-L) [4]
closely related to the human ERV-L [5,6]. Fv1 blocks
MLV virus prior to integration and does not block
infection by other retroviruses [7]. On the virus side,
historically, a single amino acid (aa) in the CA protein
at position 110 is thought to determine if MLVs are B
or N tropic [8,9]. However, more recent evidence sug-
gests that residues up- or down- stream from this cano-
nical site may also influence virus susceptibility to host
immunity [10-12].
Less than a decade after Fv1 was cloned in 1996, the
tripartite motif (TRIM) family of proteins were impli-
cated in species-specific restriction of incoming retro-
viral CAs, initially referred to as the lentivirus restriction
factor or Lv1 [13-15].
Unlike Fv1 restriction, the TRIM proteins have a
broader reactivity and can act either before or after RT
depending on the invading virus and host cell species.
Rhesus TRIM5a (rhTRIM5a) can potently restrict HIV-
1 infection; conversely human TRIM5a (huTRIM5a)
has only minor effects on SIVmac and HIV-1 infectivity.
HuTRIM5a, however, can restrict MLV-N virus replica-
tion (Ref1), but not MLV-B or-NB virus infection
[14,16]. Interestingly, mutations in the B30.2/SPRY
domain of huTRIM5a confer on it the ability to restrict
MLV-B, SIVmac and HIV-2 viruses [10,17]. Yan and
Kozak, [18] have described another CA mediated post
entry resistance to the ecotropic MLV AKV in a murine
cell line which is distinct from the classical Fv1
mediated restriction. This restriction is present in 3 out
of the 4 major genera of Mus species, suggesting an
extended role of Fv1 in Mus evolution and retroviral
resistance pre-dating the classical Fv1 alleles determined
for laboratory mice [19].
Evidence for Env mediated post entry restriction is
gaining momentum. Previously, we described another
lentivirus susceptibility factor termed Lv2; like Lv1 and
Ref1, Lv2 is a post-entry restriction found in some
human cells and their derivatives. However, in addition
to CA, the virus Env also has a role in Lv2 restriction.
The molecular clone non-restricted (MCN) virus derived
f r o mat i s s u ec u l t u r ea d a p t e dH I V - 2i s o l a t eh a san o n -
restricted phenotype, while the molecular clone
restricted (MCR) virus derived from a primary isolate
from the same patient is susceptible to Lv2. The Env
mediated restriction of MCR is overcome by pseudotyp-
ing viral cores with VSV-G Env. Envelope and CA sub-
stitutions between MCR and MCN retroviral vectors
pinpointed aa 74 in the Env and aa 207 in the CA as
the viral determinants for Lv2 MCR restriction [20,21].
Another post-entry HIV-1 resistance factor, termed Lv3
[22], has been described in rhesus macaques and is
dependent on CD4 and endogenous co-receptor viral
delivery. Uchil et al. [23] have pseudotyped the avian
leukaemia virus-A (ALV-A) Env onto HIV-1, MLV-N,
and MLV-B cores and described novel effects on post
viral entry in HEK293 cells transiently transfected with
different murine and human TRIMs. Together, these
studies suggest that the Env protein plays a role in med-
iating events post entry, at or during reverse
transcription.
Given such subtleties in Env and CA determinants of
intrinsic host cell resistance, we wished to determine if
the Lv2 phenotype was operative for the MLVs in
human cells. Because the huTRIM5a restriction of
VSV-G Env pseudotyped MLV-N viruses is well charac-
terised, we sought to determine the role, if any, of other
human host restriction factors on the MLV-B and
MLV-NB CAs. We tested our hypothesis by pseudotyp-
ing these CAs with two HIV-2 Envs that defined the
Lv2 restriction in HeLa/CD4 cells.
This paper describes the restriction of MLV-B and
MLV-NB viral cores in human cells when pseudotyped
with HIV-2 [20,21] and the feline endogenous virus
RD114 Envs. In comparison the same cores pseudotyped
by the gamma-retroviral gibbon ape leukaemia virus
(GALV), Amphotrophic (Ampho) MLV and the VSV-G
Envs were relatively unrestricted in HeLa/CD4 cells.
Thus we provide evidence for a novel restriction of
MLV-B and MLV-NB viruses in the human HeLa/CD4
cell line, which is dependent on the pseudotyping Env.
This restriction is distinct from the previously charac-
terised Ref1, Lv1, Lv2 and Lv3. Our data add another
layer to the intricate puzzle of the relationships between
different retroviruses and the myriad of host cell
defences they encounter.
Results
HIV-2 Envs MCN and MCR mediate MLV-B and MLV-NB
restriction in HeLa/CD4 cells which is rescued by different
retroviral Envs
Previously we had demonstrated that an Env and a CA
derived from an HIV-2 isolate, MCR, were determinants
of Lv2 restriction in HeLa/CD4 cells. In contrast, the
Env and CA derived from the MCN isolate are relatively
unrestricted in the same cells. The susceptibility of
MLV-N CA to Lv1 in human cells is well documented
[14,16,24]. Here we sought to determine if MLV-B and
MLV-NB cores would be restricted in an Lv2-like man-
ner. However, unexpectedly, we observed that if MLV-B
cores are pseudotyped with either the MCN or MCR
HIV-2 Envs they both result in a restricted phenotype in
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Page 2 of 11HeLa/CD4 cells, but not in the NP2/CD4/CXCR4 (a
permissive glioma cell line stably transduced with the
HIV receptors [25]) cells (Figure 1a). Infection on NP2/
CD4/CXCR4 is 60X (MCN) and 200X (MCR) greater
than on the restricted HeLa/CD4 cells (Figure 1b). In
contrast, the VSV-G and Ampho pseudotyped MLV-B
vectors were relatively uninhibited in both cell lines,
showing only 2X and 5X differences in infection (Fig-
ures 1a and 1b). Similar results were obtained for the
MLV-NB CA pseudotyped with these Envs (Figure 1a).
Infection of NP2/CD4/CXCR4 cells is 35X (MCN) and
160X (MCR) greater than on HeLa/CD4 cells. The
VSV-G and Ampho pseudotyped MLV-NB vectors
remain unrestricted, showing only 1X and 5X differ-
ences in infection of the two cell lines (Figure 1b). Thus
we have shown that this restriction of MLV-B and -NB
CAs is Env dependent. To further confirm that this
restriction is also dependent on viral CA, we produced
Figure 1 HIV-2 Envs MCN and MCR mediate MLV-B and MLV-NB restriction in HeLa/CD4 cells, and the restriction is rescued by
different retroviral Envs. VSV-G, MCN, MCR and Ampho MLV Envs were pseudotyped onto MLV-B and MLV-NB cores, and viral titres were
normalised on NP2/CD4/CXCR4 cells to 10% GFP +ve infection. (a) MCN and MCR pseudotyped MLV-B and MLV-NB viral vectors showed a
restricted infection of HeLa/CD4 cells when compared to NP/CD4/CXCR4 cells, while Ampho pseudotyped vectors were relatively unrestricted.
(b) Fold restriction is defined as the ratio of transduction of the non- restricted NP2/CD4/CXCR4 cells to the restricted HeLa/CD4 cell line for
MLV-B and -NB viral cores. (c) MCN Env pseudotyped HIV-2 CA (RodA delta Env GFP) is not restricted on HeLa/CD4 cells while MCR is. (d) Fold
restriction of HIV-2 CA RodA infectivity data in Figure 1c. (e) MLV-B pseudotyped with RD114 Env is restricted in HeLa/CD4 cells, GALV and HIV-1
Envs are not restricted. MLV-NB pseudotyped with RD114, GALV and HIV-1 Envs are not restricted in HeLa/CD4 cells. (f) Fold Restriction for the
MLV-B and MLV-NB cored viral vectors in Figure 1e. Data represent the average of three or more independent experiments +/- S.E.M.
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As expected, when we pseudotyped the RodA delta Env
HIV-2 core with VSV-G, MCN and MCR Envs only the
MCR Env was restricted in HeLa/CD4 cells (Figure 1c).
Specifically, the VSV-G and the MCN pseudotyped vec-
tors were unrestricted (0.6X and 4.7X difference
between NP2 and HeLa cells), while the MCR Env
showed 73X difference in infection (Figure 1d) similar
to the Lv2 phenotype described previously [20]. Hence
the restriction with MLV-B and MLV-NB is similar to
Lv2 in its HeLa/CD4 specificity and is overcome by
pseudotyping with VSV-G Env. Unlike Lv2, however,
both the MCN and MCR Envs result in a restricted phe-
notype with these viral CAs. Importantly, these results
show that HIV-2 Envs reveal a previously unreported
restriction of MLV-B and MLV-NB cores in HeLa/CD4
cells.
Next we generated retroviral vectors with HIV-1 [26],
GALV [27,28] and RD114 Envs [29]. These Envs were
chosen to expand the receptor classes of these MLV CA
for entry into human cells and have been well charac-
t e r i s e da sp s e u d o t y p i n gE n v sf o rM L Vc o r e s[ 2 9 , 3 0 ] .
GALV Env receptor, PiT1 [31] is closely related to the
Ampho Env receptor PiT2 [32,33] and HIV-1 uses the
same receptors as the HIV-2 Envs. Both MLV-B and
MLV-NB pseudotyped viral cores were rescued from the
restriction on HeLa/CD4 cells by the GALV and HIV-1
Envs (Figure 1e). The 2.4X and 5X difference in
infection for GALV and HIV-1 are comparable to the
VSV-G control (2.3X) (Figure 1f). Similarly, GALV
(1.6X), HIV-1 (4X) and RD114 (4.5X) pseudotyped
MLV-NB CAs were unrestricted (Figures 1e and 1f).
Interestingly, the RD114 Env (which uses the neutral
amino acid transporter abundantly expressed in human
cells [29]) showed the highest levels of restriction com-
pared to the VSV-G Env on the MLV-B CA (Figure 1e),
with a 16X difference in infection of the two cell lines
(Figure 1f). However, this level of restriction is less than
that conferred by the HIV-2 Envs described above.
Flow cytometry analysis demonstrates that NP2/CD4/
CXCR4 and HeLa/CD4 cells express similar levels of
receptors on their cell surface
The results above demonstrate that Env is a strong
determinant of the ability of viral core to complete early
events in replication. We next determined the HIV
receptor levels of NP2 and HeLa cells to further support
the notion that the restriction was not due to a differ-
ence in the expression of these receptors. We immunos-
tained the cells with fluorescently labelled antibodies to
CD4 and CXCR4 and used flow cytometry for their
detection. These experiments show similar log shifts in
fluorescent intensity for CD4 staining (Figure 2a) and
CXCR4 staining (Figure 2b) on both HeLa/CD4 and
NP2/CD4/CXCR4 cells. Hence, the restriction in HeLa/
CD4 cells is not due to the reduced level of receptors
Figure 2 Flow cytometry analysis shows equivalent numbers of CD4 and CXCR4 molecules on the surface of HeLa/CD4 and NP2/CD4/
CXCR4 cells. Cells were stained with Pacific blue conjugated mouse anti human CD4 and PE conjugated mouse anti human CXCR4, with
appropriate isotype and unlabelled cell controls. (a) NP2/CD4/CXCR4 and HeLa/CD4 cells showed similar log shifts in CD4 fluorescent intensity,
compared to isotype controls. (b) NP2/CD4/CXCR4 and HeLa/CD4 cells show similar log shifts in CXCR4 fluorescent intensity, compared to
isotype controls.
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on the unrestricted NP2/CD4/CXCR4 cells.
QT-PCR data demonstrate that the MLV-B and MLV-NB
restriction in HeLa/CD4 cells is post entry
We used QT-PCR to monitor retroviral transcription
initiated after viral and plasma membrane fusion.
HeLa/CD4 and NP2/CD4/CXCR4 cells were chal-
lenged with different pseudotyped viruses, at MOIs of
0.25 to 1, and incubated for 16 hrs or more to allow
RT to proceed. Negative controls for infection included
incubating virus for 5 minutes at 4°C or adding trypsin
to target cells just prior to challenge (to strip the cell
surface expression of receptors). In all cases viral
i n o c u l aw e r eD N a s et r e a t e dw i t h1 0 0u n i t sD N a s e / m l
of virus for 1 1/2 hrs 37°C and trypsinised off cells
before lysis for DNA extraction. The extracted DNA
was assessed by QT-PCR for late RT products. Primers
and probes were designed to amplify the transfer plas-
mid pCNCG with an internal GAPDH control reac-
tion. All data were normalized to the genomic GAPDH
internal control (GAPDH amplification results are not
shown).
Figure 3a (i) shows that the level of newly transcribed
DNA transcripts after O/N incubation 37°C on HeLa/
CD4 cells were equivalent (MOI 1). The corresponding
infectivity data (Figure 3a (ii)) show that the MCN pseu-
dotyped virus is, however, much less infectious com-
pared to VSV-G Env pseudotyped virus. Figure 3b (i
and ii) shows that regardless of viral Env, pseudotype
infection of NP2 cells always resulted in greater num-
bers of RT transcripts compared to infection of HeLa
cells. Importantly, however, a comparison of transcripts
produced after challenge of HeLa cells resulted in the
same number of transcripts regardless of whether the
CA was pseudotyped with restrictive or non-restrictive
Envs. The levels of RT transcripts detected correspond
to the different MOIs used to challenge cells. The corre-
sponding infectivity data (Figure 3b (iii and iv)) confirm
that in NP2 cells the transcripts result in permissive
titratable infection for both Envs, but in HeLa cells,
while the HIV-1 Env virus results in efficient infection,
the HIV-2 MCN virus is restricted.
Similar results were observed with the different pseu-
dotyped combinations described in this paper. In Figure
3c we show that the GALV and Ampho Envs produce
similar levels of transcripts in HeLa cells.
In summary, the data showed that viral transcripts
were overall reduced in HeLa cells when compared to
NP2 cells, in a dose dependent manner. Importantly,
these QT-PCR data show that the number of RT tran-
scripts for the restricted Envs are similar to the non-
restricted Envs in HeLa cells. These data thus confirm
that the restriction seen in HeLa cells is not due to a
block of viral entry at the plasma membrane, but is at a
post entry post RT level.
The observed restriction to MLV-B and MLV-NB in HeLa/
CD4 cells is not mediated by huTRIM5a
HuTRIM5a has been well documented as a restriction
to MLV-N, but not MLV-B and MLV-NB pseudotyped
with a VSV-G Env. We down regulated TRIM5a pro-
duction using specific siRNA knockdown to determine
whether or not it had a role in the restricted phenotype
described here. As shown by others, siRNA knockdown
of huTRIM5a relieved the restriction in HeLa/CD4
(with an increase from 18% to 38% in transduction) of
VSV-G pseudotyped MLV-N viral vectors, but not with
control siRNA (Figure 4a). Similar results were obtained
on NP2/CD4/CXCR4 cells (7.6% to 26.4% (data not
shown). By comparison, siRNA knockdown of
huTRIM5a did not affect the HIV-2 (MCN, MCR) and
RD114 Env mediated restriction of MLV-B CAs in the
HeLa/CD4 cells (Figure 4a). The results were similar for
MLV-NB cored viruses (Figure 4b). Therefore, the
restriction of MLV-B and MLV-NB cores, pseudotyped
b yH I V - 2a n dR D 1 1 4E n v s ,i sn o td u et ot h ed i r e c t
activity of huTRIM5a on incoming CAs.
Discussion
Here we describe a novel post entry restriction in HeLa/
CD4 cells of MLV-B and MLV-NB viral cores when
pseudotyped with two HIV-2 Envs and one RD114 Env,
demonstrating that human cells have factors other than
TRIM5a which inhibit MLV infection.
Studies of the post-entry actions of host cellular fac-
tors to block specific retroviral CAs from establishing
active infections have provided a greater understanding
of different retroviral/host interactions and their co-evo-
lution. These findings imply that retroviruses evolve
envelopes to avoid innate host defences that target ret-
roviral infections.
While the study of innate retroviral host cell immunity
to incoming CAs has typically employed VSV-G Env
pseudotyped vectors, there is a growing body of evi-
dence to suggest that the viral entry route also contri-
butes to the outcome of infection [17,20-22]. Previously,
we demonstrated the Lv2 restriction in HeLa/CD4 cells
to a molecular clone of an HIV-2 isolate, MCR. Unlike
Lv1 and Fv1, Lv2 is determined by Env in addition to
CA. Lv2 restriction is overcome by the substitution of
MCR Env/CA with either their non-restricted MCN
equivalents or with VSV-G Env [20,21]. Similarly the
Minr resistance factor [18] has recently been shown in
cells from the African pygmy mouse M. minutoides
against non lab-adapted strains of AKV ecotropic
MLVs. Minr also acts post viral entry, and is distinct
from any of the Fv1 allelic restrictions described
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FRMLV57 Envs displayed a 10- fold greater titre than
AKV Envs in NIH3T3 cells when compared to M. min-
utoides cells, and speculated that like Lv2 there may be
an Env dependent pre-RT determinant of Minr resis-
tance [18].
Given the extent to which MLV-B, MLV-NB and
MLV-N CAs have been investigated and their differ-
ences in susceptibility to Fv1 and huTRIM5a restriction
[9-12,16,17,23], we specifically determined whether or
not the delivery of MLV-B and -NB CAs into human
cells by the MCN and MCR HIV-2 Envs would affect
Figure 3 QT-PCR analysis of late reverse transcripts generated in HeLa/CD4 and NP2/CD4/CXCR4 cells challenged with restricted and
non-restricted MLV-B and MLV-NB viral vectors. MLV-B and MLV-NB cored viral vectors pseudotyped with the different Envs described in
Figure 1 were used to challenge confluent monolayers of HeLa/CD4 and NP2/CD4/CX/CR4 cells in 12 well trays with MOIs of 0.25-1. Controls for
infection included incubation of infected cells for 5 minutes at 4°C or trypsinising target cells (to strip cell surface receptors off) just prior to
infection. Normal infection involved incubating cell cultures O/N (12-16 hrs) to 48 hrs at 37°C (for the FACS equivalent). Total extracted DNA was
normalised to 250 or 500 ng/PCR reaction. Primers and probes were designed to amplify the eGFP target, with an internal genomic GAPDH
control. The data shown have been normalised to the GAPDH amplification and for the background level of transcripts seen in uninfected cell
controls for each experiment. (a) (i) MLV-B viral vectors pseudotyped with VSV-G Env, MLV-NB viral vectors pseudotyped with HIV-2 MCN Env,
cells were incubated 5 minutes at 4°C and overnight 37°C incubation, data shown are for RT transcripts detected after overnight 37°C incubation
minus the number detected for the 5 minutes at 4°C incubation for each Env, MOI of 1 (ii) Corresponding infection data (cells incubated for 48
hrs) for the QT-PCR shown in (i); (b) (i and ii) HIV-1 and HIV-2 MCN pseudotyped MLV-NB CA, titrated at MOIs 0.25-1 (iii and iv) Corresponding
infection data (cells incubated for 48 hrs) for the QT-PCR shown in (i and ii); (c) MLV-NB viral vectors pseudotyped with GALV and Ampho Envs,
cells were incubated O/N, MOI of 0.3. Data shown for the QT-PCRs are representative of 3 or more independent experiments. Error bars
represent +/- STDEV within 1 experiment.
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restriction.
Surprisingly, our data revealed a restriction distinct
from Lv-2 because both MLV-B and MLV-NB cored
viruses were restricted in HeLa/CD4 cells if pseudotyped
by either HIV-2 Env. GALV and VSV-G Envs rescued
this restriction. By comparison, the RD114 Env pseudo-
typed MLV-B virus was restricted, but not to the levels
seen with the HIV-2 Envs. It is interesting that the
MLV-NB core was not restricted if delivered by an
RD114 Env. This difference may reflect the adaptive
changes MLV-NB has undergone in relation to both
MLV-N and MLV-B typified by its lack of sensitivity to
both Fv1 and huTRIM5a activity [9-12,16,17,23].
Ampho Env pseudotyped MLV-B and MLV-NB cores
were relatively more restricted than GALV and less
Figure 4 siRNA knockdown of huTRIM5a reduces VSV-G MLV-N restriction in HeLa/CD4 cells but has no effect on MLV-B and MLV-NB.
(a) VSV-G pseudotyped MLV-N viral vectors were used to challenge HeLa/CD4 cells that were pre-treated with 50 pmol siRNA huTRIM5a, control
siRNA and untreated cells. As expected, treatment with siRNA huTRIM5a resulted in a relief of the restriction of MLV-N cores, while treatment of
cells with the control siRNA had no effect on the transduction. MLV-B viral vectors pseudotyped with restricted (MCN, MCR, RD114) and non
restricted (VSV-G, Ampho and GALV) Envs were used to infect HeLa/CD4 cells that were pre-treated with the optimal siRNA huTRIM5a
concentration determined for MLV-N (50 pmol), control siRNA or non-siRNA treated. Untreated NP2/CD4/CXCR4 cells were also infected as a
control. The siRNA huTRIM5a treated cells showed no relief of restriction of the MLV-B viral vectors. (b) As for Figure 4a, but with MLV-NB virus.
Data represent the average of three or more independent experiments +/- S.E.M.
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is well documented that GALV Env pseudotyped retro-
viral vectors show higher transduction efficiencies than
Ampho Env vectors on human cells [34]. The prevailing
hypothesis is that the discrepancy in target cell receptor
density levels of PiT1 [31] (GALV receptor) and PiT2
(Ampho receptor) contribute to these differences
[33,35]. However, we show by QT-PCR that there is no
difference in the levels of late RT transcripts between
GALV and Ampho Env vectors in HeLa/CD4 cells (Fig-
ure 3c). Hence the difference in susceptibility is unlikely
to be entirely due to just receptor density levels and per-
haps reflects subtleties in the adaptation to different
host species.
Both HIV-1 and HIV-2 use CD4 and CXCR4 as recep-
tors for entry. Unlike the HIV-2 Envs, the HIV-1 Env
pseudotyping did not restrict MLV CAs in HeLa/CD4
cells. Fluorescent receptor labelling with detection by
flow cytometry revealed similar amounts of both mole-
cules on the surface of both HeLa/CD4 and NP2/CD4/
CXCR4 cells (Figures 2a and 2b). These data suggest that
the restriction we describe is not due to a lack of entry
because of differences in receptor density. Furthermore,
t h eQ T - P C Rd a t ad e m o n s t r a t e st h a tt h el e v e l so fR T
transcripts for the restricted HIV-2 MCN and non-
restricted HIV-1 pseudotyped viruses were similar (Fig-
ures 3b (i and ii)).This conclusion is further supported by
the QT-PCR data which showed that the levels of tran-
scripts in the HeLa/CD4 cells were similar for the differ-
ent restricted and non restri c t e dE n v s( F i g u r e s3 a - c ) .
T h e s ed a t ac o m b i n e ds u g g e s tap o s te n t r y ,p o s tR T
mechanism of action involved in the HeLa/CD4 cells.
Given the data presented here and the increasing evi-
dence that host cell restriction is not solely dependent
on the susceptibility of an incoming viral CA; a central
question remains one of why/how? HIV-1 has rapidly
adapted from its SIV progenitor and led to a world-wide
HIV epidemic, whereas the closely related HIV-2 has
not. Previous studies have shown that HIV-2 replication
in primary macrophages is characterised by what is
believed to be a ‘latent state’ when compared to contin-
uous HIV-1 production [36]. It is possible that the adap-
tations of HIV-1 Env are more successful than those of
HIV-2, with HIV-1 adapting its route of entry to over-
ride some of the innate human defences it has hitherto
encountered.
Since MLV-N is restricted by huTRIM5a,w eu s e d
siRNA knockdown experiments to determine if
huTRIM5a had a role in this novel restriction of MLV-
B and MLV-NB CAs. Our data clearly demonstrated
that while the siRNA huTRIM5a treatment relieved
restriction of VSV-G pseudotyped MLV-N virus, this
w a sn o tt h ec a s ew i t hM L V - Ba n dM L V - N Bc o r e s( F i g -
ures 4a and 4b).
In summary, our data indicate that there is a novel
post entry restriction to MLV-B and -NB CAs in human
cells and provide more evidence on Env contribution of
CA restriction by innate retroviral responses.
Methods
Cell lines
HeLa/CD4 (human squamous epithelial carcinoma) cells
and human glioma cell NP2/CD4/CXCR4 [25] were
maintained in Dulbecco’s modified essential medium
(DMEM) supplemented with 10% foetal calf serum
(FCS), 60 μg of penicillin/ml, 100 μg of streptomycin/
ml, and 1 mg of G418/ml. NP2/CD4/CXCR4 DMEM
also contained 1 μg of puromycin/ml. Mus dunni tail
fibroblasts (MDTF) and 293 T cells were maintained in
DMEM supplemented with 10% FCS, with the penicillin
and streptomycin concentrations as described above.
Expression Plasmids
The mammalian expression plasmids used to generate
retroviral vectors in this study included: pMDG VSV-G
Env; pMP11-MCRenv, pMP11-sMCNenv [20], GALV
Env [37], Ampho Env [38], RD114 Env, pCIG3-N MLV-
N core, pCIG3-B MLV-B core, pCIG3 MLV-NB core,
pCNCG transfer plasmid encoding enhanced GFP
(eGFP) [39].
Production of retroviral vectors
Retroviral vectors were produced using a three plasmid
transfection system in 293 T cells as described pre-
viously [39]. 293 T cells were passaged 24 hrs prior to
transfection and seeded at 2.5-3 × 10
6 cells in a 10-cm
2
tissue culture dish. The polyethylenimine (PEI, Sigma)
transfection reagent was used in all transfections (stock
1 mg/ml). Plasmids were transfected at a ratio of 1:2:3
Env:Core:Transfer. A total of 18 μg DNA was combined
with 60 μlo f1m g / m lP E Ii n9 0 0μlo fs e r u m - f r e e
DMEM (Gibco, Invitrogen Corp.). The suspension was
vortexed briefly, incubated for 10 mins at room tem-
perature and added drop-wise to the 293 T cells. Trans-
fected cells were incubated for a minimum of 5 hrs or
O/N at 37°C (5% [vol/vol] CO2) in a humidified incuba-
tor; transfection supernatant was removed and cells
were overlaid with 10 ml of fresh 10% FCS DMEM for
48 and 72 hrs harvests of viral vector supernatants.
Transfection supernatants were filtered through a 0.45
μm-pore-size filter (Millipore, Bedford MA, USA) and
viral vector-containing medium stored in 500 μl aliquots
at -80°C until required.
Infection assays
Infection assays of different cell lines were carried out
by seeding cells at a density of 2 × 10
4 cells/well in 48-
well cell culture plates in a total volume of 500 μl
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ferent pseudotyped retroviral vectors. The next day viral
vectors were applied to the cells, in a total volume of
200 μl/well (supplemented with 5% FCS DMEM). The
medium was removed 2-3 hrs later and replaced with
fresh DMEM and the cells were cultured for a further
48 hrs before analysis for the expression of GFP positive
cells by flow cytometry with a FACScan (Becton Dickin-
son). Cells were fixed in 3 ml 3.7% formaldehyde/PBS
for 3 mins at RT, pelleted by centrifugation at 1500
RPM, washed once in 1×PBS and resuspended in 200 μl
PBS for flow cytometry. MLV-B and MLV-NB cored
virus stocks were titrated and normalised on NP2/CD4/
CXCR4 cells and MLV-N virus stocks on MDTF cells
before their addition to the target cell lines. Fold restric-
tion (x-fold) is calculated as the proportion of GFP +ve
cells in a non-restricted infection/restricted infection.
siRNA knockdown of huTRIM5a
Optimisation of HiperFect: siRNA concentrations
HeLa/CD4 cells were seeded in a 6-well plate at a den-
sity of 2 × 10
5 cells/well in a total volume of 2 ml, one
day prior to transfection. HuTRIM5a and a scrambled
control siRNA were titrated with varying volumes of
HiPerFect transfection reagent as per manufacturer’s
guidelines (QIAGEN, UK). In short, HiPerfect and siR-
NAs were individually diluted in serum free OPTIMEM,
then mixed and incubated for 10 min RT. siRNA trans-
fection mixtures were added drop wise to HeLa/CD4
cells and incubated in a total of 1 ml serum free OPTI-
MEM for 30 mins at 37°C in a humidified incubator.
Cells were overlaid with 1.5 ml fresh 10% FCS DMEM
and incubated O/N. Non siRNA treated HeLa/CD4 cells
were included as controls. The next day, siRNA trans-
fection supernatants were removed and cells were chal-
lenged with VSV-G pseudotyped MLV-N viral vectors.
Infected cells were incubated for a further 48 hrs before
flow cytometry analysis for the expression of GFP.
HeLa/CD4 cells were seeded in a 48-well plate at a den-
sity of 2 × 10
4 cells/well in a total of 500 μl, one day prior
to transfection. Optimised HiPerFect and siRNA
huTRIM5a and a control siRNA were transfected as
above and the next day transfected cells were infected
with equal amounts of MLV-B or MLV-NB viral vectors
pseudotyped with the different Env (VSV-G Env MLV-N
control) which were previously normalized on NP2/CD4/
CXCR4 cells. NP2/CD4/CXCR4 cells were infected with
equal amounts of virus as a positive control for viral infec-
tivity. Infected cells were incubated for a further 48 hrs
before flow cytometry analysis for the expression of GFP.
Detection of CD4 and CXCR4 expression on HeLa/CD4 and
NP2/CD4/CXCR4 cells
HeLa/CD4 and NP2/CD4/CXCR4 cells were seeded in 6
well plates at a density of 5 × 10
5 cells/well in a total of
2 ml DMEM culture medium. The following day, cells
were removed from the plate with 5 mM EDTA, pel-
leted and incubated with 5 μl/100 μlP B SP a c i f i cb l u e
conjugated mouse anti human CD4 and PE conjugated
mouse anti human CXCR4. Mouse anti human IgG iso-
type controls were used for each antibody and unla-
belled cells were also included as controls. Cells were
stained at RT for 1 hr then washed and fixed for flow
cytometry analysis.
Quantitative late PCR
HeLa/CD4 and NP2/CD4/CXCR4 cells were seeded in a
1 2 - w e l lp l a t ea tad e n s i t yo f8×1 0
4 cells/well in a total
volume of 1 ml, one day prior to infection. The following
day, the spent medium was replaced with up to 1 ml of
fresh medium containing 4 × 10
4 -1.6 × 10
5 IUs/ml (MOI
of 0.25-1) of viral vectors. All vector stocks were pre-trea-
ted with 100 U of DNaseI/ml virus for 1 hr 30 mins at 37°
C ([40]) to degrade excess plasmid DNA from the transfec-
tion stage. Normal infections were incubated O/N 37°C.
Controls for infection included trypsinising the cells just
prior to infection in 10× Trypsin/EDTA for 15 minutes at
37°C (to strip off the cell surface receptor expression) or
absorbing virus at 4°C for 5 minutes with immediate lysis.
All virus incocula were trypsinised off infected cells after
the appropriate incubation times and temperatures, fol-
lowed by 2× washes in 10× Trypsin/EDTA, before lysis
and DNA extraction with a QIAamp blood DNA mini kit
according to the manufacturer’s protocol (QIAGEN, UK).
The isolated DNA was subjected to quantitative PCR
(QT-PCR) to determine the late GFP RT transcripts pre-
sent. Each 25 μl reaction mixture for the detection of late
GFP RT DNA transcripts contained the following compo-
nents: 1× MegaMix PCR buffer (Microzone Limited), 400
nM forward primer (5’-CAACAGCCACAACGTCTA-
TATCAT-3’), 400 nM reverse primer (5’-ATGT-
TGTGGCGGATCTTGAAG-3’), 100 nM probe (5’-6-
carboxyfluorescein- CCGACAAGCAGAAGAACGGCAT-
CAA -6- carboxy-tetrafluorescein-3’), and 500 ng of total
DNA. As a control for the total amount of DNA used in
each reaction, GAPDH forward and reverse primers and a
CY5 probe were also included in each sample tested. A
standard curve was prepared with the pCNCG transfer
plasmid in a background of 200 ng of salmon sperm car-
rier genomic DNA (data not shown).
PCR amplifications, data acquisition, and analysis were
performed with the ABI PRISM 7500 sequence detec-
tion system. PCR conditions consisted of one cycle of
denaturation (95°C for 5 min) followed by 40 cycles of
amplification (95°C for 15 s, 60°C for 1 min).
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